Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Gro… (NCT04047186) | Clinical Trial Compass
CompletedPhase 2
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules
China12 participantsStarted 2019-07-01
Plain-language summary
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a pilot study
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* not less than two GGNs on chest CT
* at least one lesion is diagnosed as NSCLC from biopsy pathology
* no contraindication for surgery
* ECOG score of 0 or 1
* no detectable evidence of distant metastasis
Exclusion Criteria:
* medical history of malignancy
* pregnant or breeding period
* severe organ failure (heart, liver, kidney, and lung)
* high risk of cerebral-cardiovascular evens
* infection out of control
* received or receiving chemo- and radiotherapy
* history of severe reaction due to allergy or hypersensitivity
* severe mental disorder
* currently been enrolled in other trials
* autoimmune or chronic inflammatory disease